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Hormone replacement therapy reduces lipid oxidation 
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ABSTRACT
Background: The	first	step	in	atherosclerosis	formation	is	the	ingurgitation	of	an	oxidized	low‑density	lipid	(LDL)	
molecule by a macrophage which then turns into a foam cell within the vascular wall and initiates a cascade 
of	inflammatory	responses.	Could	it	be	that	the	potential	cardioprotective	effect	observed	in	women	receiving	
hormone replacement therapy (HRT) is modulated by estrogen’s capacity to decrease LDL oxidation in the 
vascular wall and thus decrease atherosclerotic foam cells?
Materials and Methods: Thirty-four adult female Wistar rats were divided into three groups. All were double 
oophorectomized. After recovery, Group 1 received Estradiol Valerate subcutaneous (SC) (2.5 mg/kg/week), 
Group	2	Estradiol	Valerate	SC	(2.5	mg/kg/week)	+	Progesterone	SC	(10	mg/kg/48	h),	and	Group	3	Placebo	
SC.	After	10	weeks,	all	rats	were	sacrificed	and	a	vascular	dissection	performed.	Malondialdehyde	(MDA)	was	
measured directly on the vascular extract to determine lipid oxidative levels and HRTs’ effect. Renal and hepatic 
tissue was also studied. Total antioxidant status (TAS) was measured to determine overall oxidative behavior.
Results: Vascular MDA levels for Group 1 = 80.80 (±16.8) µmol/ml/g, Group 2 = 107.69 (±24.9) µmol/ml/g, and 
Group 3 = 140.96 (±32.4) µmol/ml/g. ANOVA (P < 0.05), with a post hoc Bonferroni corrective t-test, showed that 
both	Group	1	and	2	have	statistically	significant	lower	levels	of	MDA	than	Group	3.	Renal	tissue	showed	less	
oxidative damage in the HRT groups, while hepatic tissue showed an inverse behavior with less lipid oxidation 
in the placebo group. TAS decreased with oophorectomy in all groups but decreased less in both groups that 
received HRT compared to placebo (P < 0.05).
Conclusion: HRT	significantly	reduces	lipid	oxidation	directly	in	the	arterial	wall.
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INTRODUCTION
Cardiovascular disease (CVD), and it is complications, 
continues to be, by far, the main cause of  death in 
postmenopausal women in Europe and the United 
States.[1] Some developing countries such as Costa Rica 
are also showing this trend of  increased cardiovascular 
mortality, and it has become a main topic of  public 
health.[2]
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Atherosclerotic lesions have been directly linked to being 
the cause of  vascular occlusion leading to acute myocardial 
infarction and ischemic stroke.[3] The physiopathological 
process leading up to these vascular lesions begins with the 
migration of  monocytes to the intima layer of  the arteries 
where they differentiate into macrophages. Once these 
macrophages come in contact with the fatty streak, oxidized 
low-density lipid (ox-LDL) molecules are presented to them 
through CD-34, these macrophages ingurgitate the ox-LDL 
and become foam cells.[4,5] It is these foam cells that initiate 
a chemotactic process that includes the liberation of  radical 
oxygen species, metalloproteinase, myeloperoxidase, and 
interleukin 1, which in turn attract more macrophages 
to the site and also cause oxidative damage to the LDL 
deposited in the fatty streak, therefore, promoting a loop 
which favors the formation of  more atherosclerotic plaque. 
It is this plaque that progressively reduces the lumen of  
the arteries inducing shear stress which causes turbulent 
blood flow at the site and favors the rupture of  the plaque, 
giving way to possibly catastrophic outcomes.[6] The key 
point in this pathophysiological process is understanding 
that the LDL molecule has to be oxidized in order for the 
macrophage to ingurgitate it, if  the LDL is not oxidized the 
macrophage will not ingurgitate it, and thus, not become 
a foam cell.[4-6]
Estrogens, per se, can act as free radical scavengers due to 
their phenol ring. Many previous authors have published 
in vitro studies that show how estrogens can reduce 
oxidative damage to molecules such as LDL, CuSO4, and 
DNA.[7,8] Estrogens can also induce the formation of  
other protective enzymatic antioxidants such as superoxide 
dismutase (SOD).[9] In addition, in a previous study, our 
group was able to show that estrogens have the capacity to 
directly decrease lipid oxidation in postmenopausal women 
who used hormone replacement therapy (HRT).[10] It is 
through this mechanism of  action that allows us to link 
estrogens to a possible cardioprotective effect.
Premenopausal women have relatively low incidence of  
CVD compared to men, but once women reach menopause 
and their estrogen levels decrease, it is quickly observed how 
CVD increases and how it soon surpasses the incidence 
observed in men.[11,12] The “window of  opportunity” tells 
us that if  we initiate HRT early in postmenopausal women, 
we will observe a predominately cardioprotective effect.[13] 
Observational studies enrolling only early postmenopausal 
women showed an average of  30%–50% decrease of  risk 
for coronary heart disease with HRT.[14-16] Furthermore, 
an open-label prospective study such as The Danish 
Osteoporosis Study has confirmed this data and one of  
its composite endpoints showed a 49% reduction in risk 
for coronary heart disease over a 16 year period in users 
of  HRT.[17] The 11-year cumulative follow-up of  the 
estrogen-only arm with regards to coronary disease of  the 
Women’s Health Initiative showed a heart rate of  0.96.[18] A 
meta-analysis done by Salpeter et al., which included only 
early postmenopausal women, showed a 39% reduction in 
total mortality.[19] We propose that, during the reproductive 
period, estrogens physiologically modify the oxidative 
status of  the arterial wall, inhibiting or at least delaying the 
oxidation of  LDL molecules and therefore the initiation of  
the atherosclerotic plaque. Once women enter menopause, 
and thus, lose the anti-oxidative effect offered by estrogens, 
LDL oxidation rate is increased, and the progression of  the 
atherosclerotic plaque is unopposed. We set out to show 
that estrogens have an anti-oxidative effect on vascular 
lipids and that lipid oxidation would be decreased at this 
level with the use of  estrogen-based HRT. The inclusion 
of  other key organs such as kidney and liver may also shed 
new information in this field.
MATERIALS AND METHODS
Animals
Due to the nature of  the biological tissue required for 
analysis, an animal model was selected to carry out our 
protocol. Thirty-four adult female Wistar rats were 
obtained from the University of  Costa Rica’s Center for 
Animal Research. All weighed between 240 and 315 g at 
the beginning of  the study. They were kept in a low-stress 
environment with a controlled temperature between 
21 and 25°C. 12 h day–12 h night cycles were maintained 
during the greater part of  the study, and all rats were 
kept in individual cages and received unrestricted water 
and daily feeding. The protocol was approved by the 
University’s Bioethical Committee and was in accordance 
to international standards for animal research.
Bilateral oophorectomy
All the rats had a double oophorectomy performed to 
induce a menopausal model. Antiseptic solution using 
topic 3% chlorhexidine was applied on all of  the abdomen. 
Anesthesia was carried out with an intraperitoneal 
injection of  a mixture of  ketamine at a dose of  90 mg/kg 
and xylazine at a dose of  6 mg/kg.[20,21] Great care was 
carried out to avoid any kind of  pain during and after the 
procedure. Local, subcutaneous (SC) lidocaine was applied 
in the area where the incision was going to be carried out. 
Preoperative metamizol was applied subcutaneously at a 
dose of  200 mg/kg.[21] A low, midline incision was carried 
out, with careful dissection the ovaries were identified and 
removed bilaterally. Closure was carried out with individual 
4-0 nylon sutures. Twenty-four hours after oophorectomy, 
all the rats received one more dose of  metamizol for pain 
control.
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Groups and medication
After allowing a week of  recovery, the rats were divided into 
three groups. Group 1 (#12 rats) received Estradiol Valerate 
by SC injection (2.5 mg/kg/week), Group 2 (#12 rats) 
Estradiol Valerate SC (2.5 mg/kg/week) + Progesterone 
SC (10 mg/kg/48 h), and Group 3 (#10 rats) Placebo 
SC. Based on previous studies using ovariectomized rats, 
intermediate doses were used to try to mimic “normal” 
hormonal levels and thus better represent menopausal 
hormone therapy in women.[22-28] Since sesame seed oil was 
used to dilute the progesterone in Group 2, it was also used 
as the placebo in Group 3.
Samples and measurements
Serum was obtained from whole blood extracted at 
baseline (preoophorectomy) and then again at the time of  
sacrifice to evaluate total antioxidant status (TAS). TAS[29] 
was measured using 1, 1-diphenyl-2-picrylhydrazyl (DPPH) 
which is a stable purple colored free radical. Once an 
antioxidant is added to DPPH, it is reduced and its’ color 
changes to yellow. This change in color is proportional to 
the antioxidants’ capacity of  the added substance and can 
be measured spectrophotometrically at 517 nm.
After 10 weeks of  medication, the rats were sacrificed by 
guillotine. Immediately after, a complete midline incision was 
performed to expose the rat’s circulatory system. Resection 
of  the aortic arch, the renal arteries and the bifurcation of  
the iliac arteries all the way to the femoral arteries was carried 
out. The liver and kidneys were also removed.
Vascular tissue was rinsed first with saline and then with 
buffer solution, after which they were minced with a scalpel 
and homogenized during 1 min with an Ultra-Turrax. Tubes 
were then centrifuged at 4000 rpm for 10 min at 4°C. The 
supernante fraction was removed and analyzed. The whole 
liver and both kidneys were also minced separately and 
processed in a similar fashion.
Lipid peroxidation was measured in the tissues using 
a standardized TBARS Assay Kit (Cayman Chemicals 
#10009055). The measurement of  thiobarbituric 
acid (TBA) reactive substances is the most widely employed 
assay used to determine lipid peroxidation by measuring 
malonaldehyde, which is a naturally occurring by-product of  
lipid peroxidation.[30,31] The malondialdehyde (MDA)-TBA 
adduct formed by the reaction is measured colorimetrically 
at 532 nm. All tests were done in duplicates.
RESULTS
All rats completed the study protocol, and there was no 
evidence of  complications from the surgical procedure 
which would modify the oxidative status of  the animals. 
Weight and behavioral patterns were normal throughout 
the study period.
TAS measured at baseline showed no difference among 
the three groups reflecting similar antioxidant status 
among them. After oophorectomy, all three groups 
showed a statistically significant decrease in their TAS 
compared to baseline. The placebo group suffered 
the greatest decline in their antioxidant status and was 
significantly lower than the two groups that received 
HRT [Table 1].
Regarding lipid oxidation, Table 2 shows that Group 3, 
which received placebo, had much higher levels of  
MDA compared to Groups 1 and 2, which received 
HRT, (P ≤ 0.05), indicating that the groups that 
did receive hormone replacement had lower levels 
of  lipid oxidation in their vascular extracts. When 
comparing Group 1 with Group 2, there seems to be 
a lower level of  lipid oxidation in the estrogen-only 
group compared to the estrogen/progesterone group; 
nevertheless, this difference was not statistically 
significant, ANNOVA (P < 0.05), with a post hoc 
Bonferroni corrective t-test. Renal MDA levels showed 
less lipid oxidation in both groups that received 
HRT (P < 0.05). Hepatic tissue showed an inverse 
behavior, expressing a lower level of  lipid oxidation in 
the group which received placebo, being significantly 
lower than the E2V/Pro and E2V groups (P < 0.05).
Table 1: Serum total antioxidant status at baseline 
before oophorectomy and 8 weeks after with hormone 
replacement according to group
TAS
DPPH (reduction percentage)
Baseline 8 weeks postoophorectomy
E2V/Pro (n=12) 51.34 (±9.8) 33.98 (±5.8)*
E2 (n=12) 57.90 (±6.6) 23.82 (±4.4)*
Placebo (n=10) 52.01 (±6.9) 18.20 (±4.0)*,**
*P≤0.05 with regard to baseline, **P≤0.05 with regard to other groups. TAS: Total 
antioxidant status, DPPH: 1,1‑diphenyl‑2‑picrylhydrazyl
Table 2: Determination of lipid oxidation in rat vascular, 
renal, and hepatic extracts through malondialdehyde levels 
according to hormone replacement status
Malondialdehyde (µmol/ml/g)
E2V/Pro (n=12) E2V (n=12) Placebo (n=10)
Vascular tissue 107.69 (±24.9) 80.80 (±16.8) 140.96 (±32.4)*
Renal tissue 108.44 (±28.3) 126.73 (±14.1) 156.44 (±27.7)*
Hepatic tissue 16.37 (±1.6) 16.18 (±1.3) 12.32 (±1.2)*
*P≤0.05 with regard to other groups. E2V: Estradiol valerate, Pro: Progesterone
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DISCUSSION
TAS has been proven to decrease after menopause. A review 
of  the literature has shown that this may be due to either 
an increase of  oxidative stress or a decrease of  antioxidant 
enzymes in the body.[32,33] It has also been proven that 
HRT improves this antioxidant status in postmenopausal 
women.[34] TAS of  our laboratory animals showed a similar 
behavior, with a decrease of  TAS after oophorectomy. 
The greatest decrease in TAS was observed in the group 
receiving placebo, and an overall better antioxidant status 
was maintained in both the groups that received hormone 
replacement. Nevertheless, this is a marker which shows 
the overall status of  an organism and is the sum of  all 
the individual processes that are occurring, and thus the 
importance of  analyzing tissues on an individual basis.
Recent clinical evidence has been able to reinforce the 
existence of  the timing hypothesis related to estrogens’ 
administration in early menopause.[17] This evidence 
shows that HRT may have a cardio-protective effect if  
given early compared to late in postmenopausal women.[13] 
Although there is a growing amount of  clinical data in 
this regard, there is little information on the complete 
physiopathological mechanism on how estrogen-based 
HRT would achieve the proposed cardioprotective effects.
Our group, as well as other authors, have shown that 
HRT can decrease overall lipid oxidation in women who 
receive this therapy.[10] Since lipids have a vast distribution 
in the body, a systemic decrease of  lipid oxidation may not 
be reflecting what is happening precisely at the vascular 
level where the atherosclerotic plaque is being formed. 
The fact that we were able to isolate vascular tissue and 
extract the lipids allowed us to eliminate any confounding 
factors which would modify this analysis. In Table 2, we 
see how vascular lipid oxidation levels were lower in both 
groups which received HRT compared to placebo. Under 
our controlled conditions, we can say that this decrease in 
lipid oxidation is due to the administration of  HRT. Wistar 
rats conserve 99% of  human genes and physiologically 
resemble humans very well.[35] This 10-week time laps in 
rats represent a 7-year period in a human lifespan,[35,36] 
thus suggesting that lipid oxidation at a vascular level 
may effectively be reduced using HRT during the early 
postmenopausal period. This allows us to hypothesize that 
if  there is less lipid oxidation directly at the vascular site, and 
this is a key step in foam cell formation, then there will be 
less foam cell formation, leading up to less atherosclerotic 
plaque and thus a possible cardioprotective effect.
Regarding the lower, but not statistically significant, levels 
of  lipid oxidation observed in the estrogen-only group, 
there is yet no clear explanation for this phenomenon. 
Previous authors have shown that estrogens have both 
a direct and indirect antioxidative effect. They not only 
act directly as an electron donor, but they also induce the 
formation of  some of  the most potent natural antioxidants 
enzymes available, such as SOD.[7-9,37,38] If  estrogen is solely 
acting as an antioxidant molecule, as suggested by the work 
of  Simpkins et al. and his group,[39] one would not expect 
the progestin to make much difference. On the other hand, 
if  estrogen is acting to increase biochemical antioxidant 
defenses via hormone receptors, then the progesterone 
might well attenuate this effect by causing opposing 
changes in cell antioxidant metabolism. Wassmann[40] 
published findings where they found that progesterone 
decreases estrogen-induced synthesis of  SOD in vascular 
smooth muscle. Progesterones’ role in modifying estrogens’ 
antioxidative role in vivo is yet to be defined, but this is a very 
important topic since most of  women reach menopause 
with their uterus and will require the addition of  a progestin 
to their HRT.
HRT exhibited a protective effect on lipid oxidation 
in renal tissue. These results are in accordance with a 
hormone induced renal protection previously documented 
by multiple authors and involves modulation of  
STAT3-dependant oxidative responses,[41] AGTR2[42] and 
estrogen receptor-α[43] expression. Renal physiology is a 
key determinant of  cardiovascular function and may also 
be contributing to an improved vascular oxidative status.
Regarding the analysis of  the hepatic tissue we observed 
a significant increase in lipid oxidation in both groups 
which received HRT, thus the placebo group had less 
oxidative damage at this level. Estrogen has been known 
to be a potent inductor of  certain liver enzymes, but 
when it comes to the oxidative mechanisms involved, 
there has been some mixed results. While Can[44] recently 
concluded that 17 β-estradiol was not very effective in 
preventing oxidative-induced liver damage, Sobocanec 
et al.[45] proposed that 17 β-estradiol may actually have 
a protective effect on age-related liver oxidative damage 
through Nrf2-Keap1 pathways. Compared to other organs, 
the liver may have the most complex metabolic pathways of  
all and may respond in a grand variety of  ways to specific 
metabolites. There is very little information regarding 
specific lipid oxidative pathways at the hepatic level, but 
we at least infer that estrogen might actually increase an 
oxidative path or decrease an antioxidative mechanism at 
this level.
To best of  our knowledge, this is the first study that 
analyzes estrogens’ antioxidative capacity to decrease 
lipid oxidation directly at the vascular wall as part of  the 
atherosclerotic process. Physiopathology of  CVD is a very 
complex topic but this protective effect shown by estrogens 
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may shed some light on the real gender induced difference 
shown in humans and how the approach to prevention and 
treatment may be differ in women.
CONCLUSION
Estrogen-based HRT reduces lipid oxidation directly at 
the vascular level, a process which is key to the formation 
of  the foam cell. If  foam cell formation is being reduced, 
and thus there is less formation of  atherosclerosis, this 
antioxidative mechanism may be one of  the keys to 
understanding estrogens’ cardio-protective effect when 
given early in menopause. Vascular rat models have 
previously been used to study human atherosclerotic and 
stroke physiopathology, and thus this model might give us 
an insight to what is happening in the menopausal woman, 
allowing us to explore new options. Kidney oxidative stress 
is reduced by HRT. Hormone therapy increased oxidative 
damage in liver lipids and is a result of  a complex metabolic 
system yet to be understood.
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